Multifunctional Biomimetic Nanotherapeutics for Anti-Oxidative and Anti-Inflammatory Synergistic Therapy of Corneal Neovascularization

Abstract

Corneal neovascularization (CNV) is a debilitating ocular surface disease that severely compromises visual function and carries a significant risk of vision loss. Despite its clinical impact, the development of effective and safe pharmacological treatments for CNV remains an unmet medical need. The pathogenesis of CNV is largely driven by inflammation and excessive oxidative stress. In this study, we introduce a novel nanotherapeutic strategy utilizing vanadium carbide quantum dots (V₂C QDs) with intrinsic nanozyme properties, co-encapsulated with a plasmid encoding interleukin-10 (IL-10) within a biomimetic metal-organic framework (MOF) for the treatment of CNV. To enhance targeting and biocompatibility, the nanoparticles (NPs) are further coated with mesenchymal stem cell (MSC)-derived cell membrane vesicles (CMVs), yielding the final nanomedicine designated as MOF-V₂C-Plasmid@CMVs (MVPC). In vitro studies demonstrate that MVPC NPs effectively scavenge reactive oxygen species (ROS) induced by tert-butyl hydroperoxide (tBOOH), mitigating oxidative stress. Moreover, the successful delivery and expression of the IL-10 plasmid in RAW264.7 cells result in elevated IL-10 secretion, showcasing robust anti-inflammatory activity. The CMV coating facilitates targeted delivery, enabling the efficient accumulation of MVPC NPs in the CNV region following topical administration via eye drops. In vivo experiments in CNV model rats reveal that MVPC nanotherapeutics significantly suppress neovascularization without inducing adverse effects. Collectively, this study provides proof of concept for a multifunctional nanotherapeutic platform targeting CNV, offering a promising and clinically translatable approach for the treatment of this challenging ocular disease.

Keywords

anti-inflammatory therapy / anti-oxidative therapy / biomimetic nanomedicine / corneal neovascularization / vanadium carbide

References

[1] K. M. Meek and C. Knupp, “Corneal Structure and Transparency,” Progress in Retinal and Eye Research 49 (2015): 1-16.

[2] M. O. Price, J. S. Mehta, and U. V. Jurkunas, “Corneal Endothelial Dysfunction: Evolving Understanding and Treatment Options,” Progress in Retinal and Eye Research 82 (2021): 100904.

[3] H. Wu, J. Ye, M. Zhang, et al., “A SU6668 Pure Nanoparticle-Based Eyedrops: Toward Its High Drug Accumulation and Long-Time Treatment for Corneal Neovascularization,” Journal of Nanbiotechnology 22, no. 1 (2024): 290.

[4] Y. Yang, J. Zhong, D. Cui, and L. D. Jensen, “Up-to-Date Molecular Medicine Strategies for Management of Ocular Surface Neovascularization,” Advanced Drug Delivery Reviews 201 (2023): 115084.

[5] R. Sun, S. Ma, X. Chen, et al., “Inflammation-Responsive Molecular-Gated Contact Lens for the Treatment of Corneal Neovascularization,” Journal of Controlled Release 360 (2023): 818-830.

[6] J. Zhou, Y. Cai, T. Li, et al., “Aflibercept Loaded Eye-Drop Hydrogel Mediated With Cell-Penetrating Peptide for Corneal Neovascularization Treatment,” Small 20, no. 2 (2024): e2302765.

[7] H. Zhu, J. Ye, Y. Wu, et al., “A Synergistic Therapy with Antioxidant and Anti-VEGF: Toward Its Safe and Effective Elimination for Corneal Neovascularization,” Advanced Healthcare Materials 13, no. 5 (2023): 2302192.

[8] K. Zhang, H. Zhang, Y. H. Gao, et al., “A Monotargeting Peptidic Network Antibody Inhibits More Receptors for Anti-Angiogenesis,” ACS Nano (2021): 13065-13076.

[9] H. Zhang, K. Zhang, Q.-S. Zhang, et al., “A Peptidic Network Antibody Inhibits Both Angiogenesis and Inflammatory Response,” Journal of Controlled Release 362 (2023): 715-725.

[10] J. Ye, Y. Cheng, X. Wen, et al., “Biomimetic Nanocomplex Based Corneal Neovascularization Theranostics,” Journal of Controlled Release 374 (2024): 50-60.

[11] Z. Zeng, S. Li, X. Ye, et al., “Genome Editing VEGFA Prevents Corneal Neovascularization In Vivo,” Advanced Science 11, no. 25 (2024): e2401710.

[12] S. Sood, A. Tiwari, J. Sangwan, et al., “Role of Epigenetics in Corneal Health and Disease,” Progress in Retinal and Eye Research 104 (2024): 101318.

[13] Q. Luo, J. Yang, H. Xu, et al., “Sorafenib-Loaded Nanostructured Lipid Carriers for Topical Ocular Therapy of Corneal Neovascularization: Development, In-Vitro and In Vivo Study,” Drug Delivery 29, no. 1 (2022): 837-855.

[14] V. Romano, N. Spiteri, and S. B. Kaye, “Angiographic-Guided Treatment of Corneal Neovascularization,” JAMA Ophthalmology 133, no. 3 (2015): e143544.

[15] B. Senturk, M. O. Cubuk, M. C. Ozmen, B. Aydin, M. O. Guler, and A. B. Tekinay, “Inhibition of VEGF Mediated Corneal Neovascularization by Anti-Angiogenic Peptide Nanofibers,” Biomaterials 107 (2016): 124-132.

[16] A. Mukwaya, L. Jensen, B. Peebo, and N. Lagali, “MicroRNAs in the Cornea: Role and Implications for Treatment of Corneal Neovascularization,” Ocular Surface 17, no. 3 (2019): 400-411.

[17] D. Roshandel, M. Eslani, A. Baradaran-Rafii, et al., “Current and Emerging Therapies for Corneal Neovascularization,” The Ocular Surface 16, no. 4 (2018): 398-414.

[18] K. Wang, L. Jiang, Y. Zhong, et al., “Ferrostatin-1-Loaded Liposome for Treatment of Corneal Alkali Burn via Targeting Ferroptosis,” Bioengineering & Translational Medicine 7, no. 2 (2022): e10276.

[19] M. Saraiva, P. Vieira, and A. O'Garra, “Biology and Therapeutic Potential of Interleukin-10,” Journal of Experimental Medicine 217, no. 1 (2020): e20190418.

[20] R. A. Saxton, N. Tsutsumi, L. L. Su, et al., “Structure-Based Decoupling of the Pro- and Anti-Inflammatory Functions of Interleukin-10,” Science 371, no. 6535 (2021): eabc8433.

[21] W. Ouyang, S. Rutz, N. K. Crellin, P. A. Valdez, and S. G. Hymowitz, “Regulation and Functions of the IL-10 family of Cytokines in Inflammation and Disease,” Annual Review of Immunology 29 (2011): 71-109.

[22] W. K. Eddie Ip, N. Hoshi, D. S. Shouval, S. Snapper, and R. Medzhitov, “Anti-Inflammatory Effect of IL-10 Mediated by Metabolic Reprogramming Ofmacrophages,” Science 356, no. 6337 (2017): 513-519.

[23] T. Bu, Z. Li, Y. Hou, et al., “Exosome-Mediated Delivery of Inflammation-Responsive Il-10 mRNA for Controlled Atherosclerosis Treatment,” Theranostics 11, no. 20 (2021): 9988-10000.

[24] S. Bido, M. Nannoni, S. Muggeo, et al., “Microglia-Specific IL-10 Gene Delivery Inhibits Neuroinflammation and Neurodegeneration in a Mouse Model of Parkinson's Disease,” Science Translational Medicine 16, no. 761 (2024): eadm8563.

[25] M. Gao, M. Tang, W. Ho, et al., “Modulating Plaque Inflammation via Targeted mRNA Nanoparticles for the Treatment of Atherosclerosis,” ACS Nano 17, no. 18 (2023): 17721-17739.

[26] X. Xie, J. Jiang, X. Liu, et al., “Interleukin-10 Plasmid Delivery by Polymeric Nanocarrier Shows Efficient and Safe Tissue Repair in Acute Muscle Damage Models in Mice,” Nano Today 46 (2022): 101544.

[27] M. Su, Q. Dai, C. Chen, Y. Zeng, C. Chu, and G. Liu, “Nano-Medicine for Thrombosis: A Precise Diagnosis and Treatment Strategy,” Nano-Micro Letters 12, no. 1 (2020): 96.

[28] J. Zhuang, H. Gong, J. Zhou, et al., “Targeted Gene Silencing In Vivo by Platelet Membrane-Coated Metal-Organic Framework Nanoparticles,” Science Advances 6, no. 13 (2020): eaaz6108.

[29] J. Zhang, H. Yu, M. Q. Man, and L. Hu, “Aging in the Dermis: Fibroblast Senescence and Its Significance,” Aging Cell 23, no. 2 (2024): e14054.

[30] J. Gu, P. Zhang, H. Li, et al., “Cerium-Luteolin Nanocomplexes in Managing Inflammation-Related Diseases by Antioxidant and Immunoregulation,” ACS Nano 18, no. 8 (2024): 6229-6242.

[31] J. Liu, X. Han, T. Zhang, K. Tian, Z. Li, and F. Luo, “Reactive Oxygen Species (ROS) Scavenging Biomaterials for Anti-Inflammatory Diseases: From Mechanism to Therapy,” Journal of Hematology & Oncology 16, no. 1 (2023): 116.

[32] Y. Zhang, W. Liu, X. Wang, Y. Liu, and H. Wei, “Nanozyme-Enabled Treatment of Cardio- and Cerebrovascular Diseases,” Small 19, no. 13 (2023): e2204809.

[33] C. Peng, R. Pang, J. Li, and E. Wang, “Current Advances on the Single-Atom Nanozyme and Its Bioapplications,” Advanced Materials 36, no. 10 (2024): e2211724.

[34] Y. Wang, X. Jia, S. An, W. Yin, J. Huang, and X. Jiang, “Nanozyme-Based Regulation of Cellular Metabolism and Their Applications,” Advanced Materials 36, no. 10 (2024): e2301810.

[35] W. Feng, X. Han, H. Hu, et al., “2D vanadium Carbide MXenzyme to Alleviate ROS-Mediated Inflammatory and Neurodegenerative Diseases,” Nature Communications 12, no. 1 (2021): 2203.

[36] H. W. Guo, X. Y. Chu, Y. S. Guo, et al., “A Water Transfer Printing Method for Contact Lenses Surface 2D MXene Modification to Resist Bacterial Infection and Inflammation,” Science Advances 10, no. 15 (2024): eadl3262.

[37] M. Kou, L. Huang, J. Yang, et al., “Mesenchymal Stem Cell-Derived Extracellular Vesicles for Immunomodulation and Regeneration: A next Generation Therapeutic Tool?,” Cell Death & Disease 13, no. 7 (2022): 580.

[38] M. Zhao, S. Liu, C. Wang, et al., “Mesenchymal Stem Cell-Derived Extracellular Vesicles Attenuate Mitochondrial Damage and Inflammation by Stabilizing Mitochondrial DNA,” ACS Nano 15, no. 1 (2020): 1519-1538.

[39] Y. Song, Y. You, X. Xu, et al., “Adipose-Derived Mesenchymal Stem Cell-Derived Exosomes Biopotentiated Extracellular Matrix Hydrogels Accelerate Diabetic Wound Healing and Skin Regeneration,” Advanced Science 10, no. 30 (2023): e2304023.

[40] H. Zheng, Y. Zhang, L. Liu, et al., “One-Pot Synthesis of Metal-Organic Frameworks With Encapsulated Target Molecules and Their Applications for Controlled Drug Delivery,” Journal of the American Chemical Society 138, no. 3 (2016): 962-968.

[41] S. K. Alsaiari, S. Patil, M. Alyami, et al., “Endosomal Escape and Delivery of CRISPR/Cas9 Genome Editing Machinery Enabled by Nanoscale Zeolitic Imidazolate Framework,” Journal of the American Chemical Society 140, no. 1 (2018): 143-146.

[42] T. T. Chen, J. T. Yi, Y. Y. Zhao, and X. Chu, “Biomineralized Metal-Organic Framework Nanoparticles Enable Intracellular Delivery and Endo-Lysosomal Release of Native Active Proteins,” Journal of the American Chemical Society 140, no. 31 (2018): 9912-9920.

[43] Y. Cao, T. Wu, K. Zhang, et al., “Engineered Exosome-Mediated Near-Infrared-II Region V2C Quantum Dot Delivery for Nucleus-Target Low-Temperature Photothermal Therapy,” ACS Nano 13, no. 2 (2019): 1499-1510.

[44] D. Huang, Y. Xie, D. Lu, et al., “Demonstration of a White Laser With V2C MXene-Based Quantum Dots,” Advanced Materials 31, no. 24 (2019): e1901117.

[45] J. Yang, L. Luo, Y. Oh, et al., “Sunitinib Malate-Loaded Biodegradable Microspheres for the Prevention of Corneal Neovascularization in Rats,” Journal of Controlled Release 327 (2020): 456-466.

[46] J. Yu, Y. Wu, Q. Dai, et al., “In Vivo Assembly Drug Delivery Strategy Based on Ultra-Small Nanoparticles: Toward High Drug Permeation and Accumulation for CNV Treatment,” Chemical Engineering Journal 450 (2022): 137968.

RIGHTS & PERMISSIONS

2025 The Author(s). Aggregate published by SCUT, AIEI, and John Wiley & Sons Australia, Ltd.